Pfizer

-12.34%

Live  

Pfizer, Inc. is a multinational pharmaceutical company founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company is currently headquartered in New York City and operates in over 175 countries around the world.
Pfizer is known for its innovations in medicine, and has developed multiple blockbuster drugs, including Viagra, Lipitor, and Celebrex. The company has a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products.
Pfizer works to improve global health by providing access to quality healthcare, increasing access to medicines, and investing in medical research and development. The company also partners with organizations and governments to address public health challenges, such as addressing infectious diseases and expanding access to healthcare in emerging markets.
In addition to its focus on healthcare and pharmaceuticals, Pfizer has a strong commitment to corporate responsibility and sustainability. The company aims to reduce its environmental impact, promote diversity and inclusion, and support community outreach initiatives.
Overall, Pfizer's mission is to discover, develop, and provide innovative medicines and vaccines that improve the lives of people around the world.

Pfizer is a big company that makes medicines and vaccines to help people feel better and stay healthy. Think of them like a superhero for our health. When people get sick or need medicine to prevent getting sick, doctors often use things that Pfizer has created.
So, how does Pfizer make money? When doctors give their patients these medicines and vaccines, hospitals and pharmacies buy them from Pfizer. The companies then sell those medicines to people, and that’s how Pfizer earns money. They also get money when they create new medicines and sell them to other countries around the world.
Pfizer is successful for a few reasons. First, they spend a lot of time and money making sure their medicines are both safe and effective before they can sell them. This gives people and doctors confidence in their products. Second, Pfizer is always working on new medicines and vaccines, which means they are always looking for ways to help even more people. For example, they helped make a COVID-19 vaccine that many people got to protect themselves from the virus.
In the future, Pfizer will likely continue to be successful because there will always be a need for new medicines and vaccines. People will always get sick and need help, and scientists are always discovering new things about health, which means more opportunities for Pfizer to help. They have a good team of scientists and researchers who keep creating more ways to help people, which is why they will probably keep being successful for many years to come.

MS4gUGlvbm VlciBpbiB0 aGUgcGhhcm 1hY2V1dGlj YWwgaW5kdX N0cnk6IFBm aXplciBpcy BvbmUgb2Yg dGhlIHdvcm xkJ3Mgb2xk ZXN0IGFuZC BsYXJnZXN0 IHBoYXJtYW NldXRpY2Fs IGNvbXBhbm llcywgZXN0 YWJsaXNoZW QgaW4gMTg0 OS4gSXQgaG FzIGEgbG9u ZyBoaXN0b3 J5IG9mIGRl dmVsb3Bpbm cgYW5kIG1h bnVmYWN0dX JpbmcgaW5u b3ZhdGl2ZS BtZWRpY2lu ZXMsIG1ha2 luZyBpdCBh IHRydXN0ZW QgYnJhbmQg aW4gdGhlIG dsb2JhbCBo ZWFsdGhjYX JlIGluZHVz dHJ5Ljxicj 4yLiBTdHJv bmcgcmVzZW FyY2ggYW5k IGRldmVsb3 BtZW50OiBQ Zml6ZXIgaG FzIGEgcm9i dXN0IHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudCBw cm9ncmFtLC BpbnZlc3Rp bmcgYmlsbG lvbnMgb2Yg ZG9sbGFycy Bhbm51YWxs eSBpbiB0aG UgZGV2ZWxv cG1lbnQgb2 YgbmV3IG1l ZGljaW5lcy BhbmQgdHJl YXRtZW50cy 4gSXRzIHRl YW0gb2Ygc2 NpZW50aXN0 cywgcmVzZW FyY2hlcnMs IGFuZCBjbG luaWNpYW5z IHdvcmsgdG 9nZXRoZXIg dG8gc29sdm Ugc29tZSBv ZiB0aGUgbW 9zdCBzaWdu aWZpY2FudC BoZWFsdGhj YXJlIGNoYW xsZW5nZXMg YW5kIGltcH JvdmUgcGF0 aWVudCBvdX Rjb21lcy48 YnI+My4gR2 xvYmFsIHBy ZXNlbmNlOi BQZml6ZXIg aGFzIGEgc3 Ryb25nIGds b2JhbCBwcm VzZW5jZSwg d2l0aCBvcG VyYXRpb25z IGluIG92ZX IgMTc1IGNv dW50cmllcy BhbmQgdGVy cml0b3JpZX Mgd29ybGR3 aWRlLiBJdC BoYXMgYSBk aXZlcnNpZm llZCBwb3J0 Zm9saW8gb2 YgcHJvZHVj dHMgYW5kIH NlcnZlcyBh IGJyb2FkIH JhbmdlIG9m IHRoZXJhcG V1dGljIGFy ZWFzLCBpbm NsdWRpbmcg aW5mZWN0aW 91cyBkaXNl YXNlcywgb2 5jb2xvZ3ks IHJhcmUgZG lzZWFzZXMs IGFuZCBjYX JkaW92YXNj dWxhciBkaX NvcmRlcnMu PGJyPjQuIE ZvY3VzIG9u IGlubm92YX Rpb246IFdp dGggYSBkZW RpY2F0ZWQg YW5kIGhpZ2 hseSBza2ls bGVkIHRlYW 0gb2Ygc2Np ZW50aXN0cy BhbmQgcmVz ZWFyY2hlcn MsIFBmaXpl ciBjb250aW 51ZXMgdG8g aW5ub3ZhdG UgYW5kIGRl dmVsb3Agbm V3IHRyZWF0 bWVudHMgZm 9yIHVubWV0 IG1lZGljYW wgbmVlZHMu IEl0IGhvbG RzIG51bWVy b3VzIHBhdG VudHMgYW5k IGhhcyBzZX ZlcmFsIHN1 Y2Nlc3NmdW wgcHJvZHVj dHMsIHN1Y2 ggYXMgVmlh Z3JhLCBMaX BpdG9yLCBh bmQgUHJldm 5hci48YnI+ NS4gQ29tbW l0bWVudCB0 byBxdWFsaX R5IGFuZCBz YWZldHk6IF BmaXplciBo YXMgYSBzdH JpY3QgcXVh bGl0eSBjb2 50cm9sIHN5 c3RlbSBpbi BwbGFjZSB0 byBlbnN1cm UgdGhlIHNh ZmV0eSBhbm QgZWZmaWNh Y3kgb2YgaX RzIHByb2R1 Y3RzLiBJdC Bmb2xsb3dz IHN0cmljdC BtYW51ZmFj dHVyaW5nIH N0YW5kYXJk cyBhbmQgcm VndWxhdGlv bnMgaW4gYW xsIGl0cyBm YWNpbGl0aW VzIHdvcmxk d2lkZSB0by BkZWxpdmVy IHNhZmUgYW 5kIGVmZmVj dGl2ZSBtZW RpY2luZXMg dG8gcGF0aW VudHMuPGJy PjYuIFNvY2 lhbCByZXNw b25zaWJpbG l0eTogUGZp emVyIGlzIG NvbW1pdHRl ZCB0byBtYW tpbmcgYSBw b3NpdGl2ZS BpbXBhY3Qg b24gdGhlIG NvbW11bml0 aWVzIGl0IH NlcnZlcy4g VGhyb3VnaC BpdHMgY29y cG9yYXRlIH NvY2lhbCBy ZXNwb25zaW JpbGl0eSBp bml0aWF0aX ZlcywgdGhl IGNvbXBhbn kgc3VwcG9y dHMgdmFyaW 91cyBoZWFs dGhjYXJlIH Byb2dyYW1z LCBlZHVjYX Rpb24sIGFu ZCBlbnZpcm 9ubWVudGFs IHN1c3RhaW 5hYmlsaXR5 IGVmZm9ydH MuPGJyPjcu IFN0cm9uZy BmaW5hbmNp YWwgcGVyZm 9ybWFuY2U6 IFBmaXplci BpcyBhIGZp bmFuY2lhbG x5IHN0YWJs ZSBjb21wYW 55IHdpdGgg YSBzdHJvbm cgdHJhY2sg cmVjb3JkIG 9mIGdyb3d0 aCBhbmQgcH JvZml0YWJp bGl0eS4gSX RzIGZpbmFu Y2lhbCBzdG FiaWxpdHkg YW5kIHBlcm Zvcm1hbmNl IGFyZSByZW ZsZWN0ZWQg aW4gY29uc2 lzdGVudGx5 IGhpZ2ggc3 RvY2sgcHJp Y2VzIGFuZC BjcmVkaXQg cmF0aW5ncy 48YnI+OC4g SW5ub3ZhdG l2ZSBwYXJ0 bmVyc2hpcH M6IFBmaXpl ciBoYXMgcG FydG5lcmVk IHdpdGggb3 RoZXIgbGVh ZGluZyBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMs IGFjYWRlbW ljIGluc3Rp dHV0aW9ucy wgYW5kIGdv dmVybm1lbn QgYWdlbmNp ZXMgdG8gYW NjZWxlcmF0 ZSBpbm5vdm F0aW9uIGFu ZCBicmluZy BuZXcgdHJl YXRtZW50cy B0byBtYXJr ZXQuIFRoZX NlIGNvbGxh Ym9yYXRpb2 5zIGVuaGFu Y2UgdGhlIG NvbXBhbnkn cyByZXNlYX JjaCBjYXBh YmlsaXRpZX MgYW5kIGV4 cGFuZCBpdH MgcmVhY2gg aW4gdGhlIG dsb2JhbCBo ZWFsdGhjYX JlIG1hcmtl dC4=

UGZpemVyIG lzIGEgbXVs dGluYXRpb2 5hbCBwaGFy bWFjZXV0aW NhbCBjb21w YW55IHdpdG ggYSBidXNp bmVzcyBtb2 RlbCBiYXNl ZCBvbiByZX NlYXJjaCwg ZGV2ZWxvcG 1lbnQsIHBy b2R1Y3Rpb2 4sIGFuZCBt YXJrZXRpbm cgb2YgaW5u b3ZhdGl2ZS BhbmQgZ2Vu ZXJpYyBwcm VzY3JpcHRp b24gZHJ1Z3 MsIHZhY2Np bmVzLCBhbm QgY29uc3Vt ZXIgaGVhbH RoY2FyZSBw cm9kdWN0cy 4gSXRzIGJ1 c2luZXNzIG 9wZXJhdGlv bnMgYXJlIH NlZ21lbnRl ZCBpbnRvIH RocmVlIG1h aW4gYXJlYX M6IElubm92 YXRpdmUgSG VhbHRoLCBF c3NlbnRpYW wgSGVhbHRo LCBhbmQgQ2 9uc3VtZXIg SGVhbHRoY2 FyZS48YnI+ VGhlIElubm 92YXRpdmUg SGVhbHRoIH NlZ21lbnQg Zm9jdXNlcy BvbiBkZXZl bG9waW5nIG FuZCBjb21t ZXJjaWFsaX ppbmcgbmV3 IG1lZGljaW 5lcyBpbiBh cmVhcyBzdW NoIGFzIG9u Y29sb2d5LC BpbmZsYW1t YXRpb24gYW 5kIGltbXVu b2xvZ3ksIH JhcmUgZGlz ZWFzZXMsIG FuZCB2YWNj aW5lcy4gVG hpcyBpbmNs dWRlcyBpbn Zlc3Rpbmcg aW4gcmVzZW FyY2ggYW5k IGRldmVsb3 BtZW50IHRv IGRpc2Nvdm VyIG5ldyB0 cmVhdG1lbn RzLCBvYnRh aW5pbmcgcm VndWxhdG9y eSBhcHByb3 ZhbCwgYW5k IG1hcmtldG luZyBhbmQg c2VsbGluZy B0aGVtIHdv cmxkd2lkZS 48YnI+VGhl IEVzc2VudG lhbCBIZWFs dGggc2VnbW VudCBwcmlt YXJpbHkgZm 9jdXNlcyBv biB0aGUgcH JvZHVjdGlv biBhbmQgc2 FsZSBvZiBl c3RhYmxpc2 hlZCBnZW5l cmljIG1lZG ljaW5lcywg YXMgd2VsbC BhcyBiaW9z aW1pbGFycy 4gVGhlc2Ug YXJlIGxvd2 VyLWNvc3Qg YWx0ZXJuYX RpdmVzIHRv IGJyYW5kZW QgZHJ1Z3Mg YW5kIGFyZS BwcmltYXJp bHkgdXNlZC B0byB0cmVh dCBjb21tb2 4gY29uZGl0 aW9ucyBzdW NoIGFzIGh5 cGVydGVuc2 lvbiBhbmQg ZGlhYmV0ZX MuPGJyPlRo ZSBDb25zdW 1lciBIZWFs dGhjYXJlIH NlZ21lbnQg aW5jbHVkZX Mgb3Zlci10 aGUtY291bn RlciAoT1RD KSBwcm9kdW N0cyBzdWNo IGFzIG51dH JpdGlvbmFs IHN1cHBsZW 1lbnRzLCBw YWluIHJlbG lldmVycywg YW5kIHBlcn NvbmFsIGNh cmUgaXRlbX MuIFRoZXNl IHByb2R1Y3 RzIGFyZSBz b2xkIGRpcm VjdGx5IHRv IGNvbnN1bW VycyB3aXRo b3V0IGEgcH Jlc2NyaXB0 aW9uIGFuZC BhcmUgd2lk ZWx5IGF2YW lsYWJsZSBp biByZXRhaW wgc3RvcmVz Ljxicj5QZm l6ZXIncyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIHN0 cmF0ZWdpYy BwYXJ0bmVy c2hpcHMgYW 5kIGNvbGxh Ym9yYXRpb2 5zIHdpdGgg b3RoZXIgcG hhcm1hY2V1 dGljYWwgY2 9tcGFuaWVz LCBhY2FkZW 1pYyBpbnN0 aXR1dGlvbn MsIGFuZCBn b3Zlcm5tZW 50IG9yZ2Fu aXphdGlvbn MgdG8gZnVy dGhlciBlbm hhbmNlIHRo ZWlyIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudCBl ZmZvcnRzLj xicj5PdmVy YWxsLCBQZm l6ZXIncyBi dXNpbmVzcy Btb2RlbCBp cyBjZW50ZX JlZCBvbiBp bm5vdmF0aW 9uLCBtYXJr ZXQgZXhwYW 5zaW9uLCBh bmQgY29sbG Fib3JhdGlv biB0byBwcm 92aWRlIGEg ZGl2ZXJzZS Bwb3J0Zm9s aW8gb2YgcH JvZHVjdHMg dGhhdCBpbX Byb3ZlIHRo ZSBoZWFsdG ggYW5kIHdl bGwtYmVpbm cgb2YgcGVv cGxlIGFyb3 VuZCB0aGUg d29ybGQu

AI does pose certain risks to Pfizer’s products, services, and competitive positioning, although the extent of these threats may vary.
1. Substitution: AI-driven pharmaceutical technologies could lead to the development of alternative therapies or treatments that may circumvent traditional pharmaceutical approaches. For instance, AI can optimize drug discovery and development processes, potentially leading to faster and more cost-effective treatments that challenge Pfizer’s existing product lines. Advances in biotechnology, including gene editing and personalized medicine facilitated by AI, could produce therapies that compete directly with Pfizer’s offerings.
2. Disintermediation: AI has the potential to streamline healthcare delivery, which might reduce the need for intermediaries, such as healthcare providers or pharmaceutical sales representatives. For example, telemedicine platforms powered by AI could lower barriers to accessing medications, allowing patients to obtain treatments through direct-to-consumer models. This shift could disrupt Pfizer’s traditional distribution channels and market strategies.
3. Margin Pressure: The increasing use of AI can lead to more efficient drug development processes, potentially lowering the cost of bringing new drugs to market. While this could result in lower prices for consumers, it may also put pressure on Pfizer’s profit margins. If competitors leverage AI effectively to reduce costs, Pfizer might face challenges in maintaining pricing power for its products.
Overall, while AI presents opportunities for innovation and efficiency, it also introduces competitive pressures that could impact Pfizer’s market positioning and profitability. The company would need to adapt by investing in AI technologies and developing strategies to mitigate these risks.

The sensitivity of Pfizer’s earnings, cash flow, and valuation to changes in interest rates can be analyzed through several key factors:
1. Earnings Sensitivity: Changes in interest rates can affect Pfizer’s earnings primarily through their impact on the cost of borrowing and investment decisions. If interest rates rise, the cost of financing existing debt may increase, potentially reducing net income. Additionally, higher rates could lead to decreased consumer spending and healthcare investment, which might lower demand for Pfizer’s products, particularly in noessential categories.
2. Cash Flow Sensitivity: Pfizer’s cash flow can also be sensitive to interest rate changes. Higher interest rates can result in increased interest expenses, which would decrease operating cash flow. Additionally, an environment of rising rates may slow down economic growth, potentially impacting sales and, subsequently, cash flows from operations. Conversely, if rates decrease, Pfizer might benefit from lower borrowing costs, enhancing cash flow.
3. Valuation Sensitivity: The valuation of Pfizer, often assessed through discounted cash flow (DCF) models, is significantly affected by interest rates. Higher interest rates increase the discount rate used to calculate the present value of future cash flows, typically resulting in a lower valuation. In contrast, lower rates would decrease the discount rate and could potentially enhance valuation. Moreover, shifts in interest rates can impact investor sentiment and risk perception, which can also influence stock price movements.
4. Market Conditions: The broader market can amplify Pfizer’s sensitivity to interest rate changes. For instance, when rates rise, it might lead to a rotation out of growth stocks, affecting valuation multiples. Changes in interest rates may also influence regulatory and reimbursement environments, further affecting Pfizer’s business dynamics.
In summary, Pfizer’s earnings, cash flow, and valuation are notably sensitive to changes in interest rates due to their impact on borrowing costs, consumer demand, and overall economic conditions. Each increase or decrease in rates can have downstream effects that may influence the company’s financial health and market perception.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvR0 5XR3NZUk52 aVNJZlhrZm pHamcud2Vi cCIgYWx0PS JQZml6ZXIi IHRpdGxlPS JQZml6ZXIi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgUGZpemVy PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag4pyFIERv d25sb2FkID xpPiJUaGUg Q2hlY2tsaX N0IFZhbHVl IEludmVzdG 9yIOKAlCBB IFNtYXJ0ZX IgV2F5IHRv IFBpY2sgU3 RvY2tzIjwv aT4g4oCUIH RvdGFsbHkg ZnJlZSEKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdVR1 pwZW0gVnlJ SGRoY3lCbS BiM1Z1WkdW a0lHIGx1SU RFNE5Ea2cg WW5rZ2RIZH ZJRyBOdmRY TnBibk1zIE lFTm9ZWEpz WlggTWdVR1 pwZW1WeSBJ R0Z1WkNCRG FHIEZ5YkdW eklFVnkgYU dGeWRDd2dh VyA0Z1FuSn ZiMnRzIGVX NHNJRTVsZH kgQlpiM0py TGlCVSBhR1 VnWTI5dGNH IEZ1ZVNCcG JtbDAgYVdG c2JIa2djSC BKdlpIVmpa V1FnIFkybD BjbWxqSUcg RmphV1FzSU dGdSBJR0Zz WTI5b2IyIH d0WW1GelpX UWcgWVc1MG FYTmxjSCBS cFl5d2dZVz VrIElHeGhk R1Z5SUcgVj RjR0Z1WkdW ayBJSFJ2SU hCeWIyIFIx WTJVZ2IzUm 8gWlhJZ1ky aGxiVyBsal lXeHpJR0Z1 IFpDQndhR0 Z5YlcgRmpa WFYwYVdOaC BiSE11UEdK eVBqIEl1SU VsdUlERTUg TlRBc0lGQm 1hWCBwbGNp QnlaWFp2IG JIVjBhVzl1 YVggcGxaQ0 IwYUdVZyBj R2hoY20xaF kyIFYxZEds allXd2cgYV c1a2RYTjBj biBrZ2QybD BhQ0IwIGFH VWdaR2x6WT IgOTJaWEo1 SUc5bSBJRl JsY25KaGJY IGxqYVc0c0 lIUm8gWlNC bWFYSnpkQy BCaWNtOWha QzF6IGNHVm pkSEoxYlMg QmhiblJwWW 1sdiBkR2xq TGlCVWFHIG x6SUdScGMy TnYgZG1WeW VTQnNaVyBR Z2RHOGdkR2 hsIElHRnVk R2xpYVcgOT BhV01nY21W MiBiMngxZE dsdmJpIHdn YzJGMmFXNW 4gSUdOdmRX NTBiRyBWem N5QnNhWFps IGN5QmhibV FnYVcgMXdj bTkyYVc1bi BJR2hsWVd4 MGFHIE5oY2 1VZ1lYSnYg ZFc1a0lIUm 9aUyBCM2Iz SnNaQzQ4IF luSStNeTRn VkcgaGxJR0 pzZFdVZyBj R2xzYkN3Z1 ZtIGxoWjNK aExDQjMgWV hNZ2FXNTBj bSA5a2RXTm xaQ0JpIGVT QlFabWw2Wl ggSWdhVzRn TVRrNSBPQ0 JoYm1RZ2NY IFZwWTJ0c2 VTQmkgWldO aGJXVWdiMi A1bElHOW1J SFJvIFpTQn RiM04wSUgg TjFZMk5sYz NObSBkV3dn YldWa2FXIE 5oZEdsdmJu TWcgYVc0Z2 FHbHpkRyA5 eWVTNGdTWF FnIGQyRnpJ SFJvWlMgQm 1hWEp6ZENC diBjbUZzSU cxbFpHIGxq WVhScGIyNG cgWm05eUlI Um9aUyBCMG NtVmhkRzFs IGJuUWdiMl lnWlggSmxZ M1JwYkdVZy BaSGx6Wm5W dVkzIFJwYj I0Z1lXNWsg SUdoaGN5Qm laVyBWdUlI VnpaV1FnIF lua2diV2xz YkcgbHZibk 1nYjJZZyBi V1Z1SUhkdm NtIHhrZDJs a1pTNDggWW 5JK05DNGdV RyBacGVtVn lJR2x6IElH OXVaU0J2Wm kgQjBhR1Vn YkdGeSBaMl Z6ZENCd2FH IEZ5YldGal pYVjAgYVdO aGJDQmpiMi Axd1lXNXBa WE1nIGFXNG dkR2hsSUgg ZHZjbXhrTE NCMyBhWFJv SUc5d1pYIE poZEdsdmJu TWcgYVc0Z2 IzWmxjaSBB eE1qVWdZMj kxIGJuUnlh V1Z6SUcgRn VaQ0IwWlhK eSBhWFJ2Y2 1sbGN5IDRn U1hRZ1pXMX cgYkc5NWN5 QnZkbSBWeU lEa3dMREF3 IE1DQndaVz l3YkcgVWdZ VzVrSUdoaC BjeUJoSUhK bGRtIFZ1ZF dVZ2IyWWcg YjNabGNpQW tOVCBBZ1lt bHNiR2x2IG JpNDhZbkkr TlMgNGdWR2 hsSUdOdiBi WEJoYm5rZ2 FYIE1nWTI5 dGJXbDAgZE dWa0lIUnZJ RyBkc2IySm hiQ0JvIFpX RnNkR2dnWV cgNWtJR2ho Y3lCdCBZV1 JsSUhOcFoy IDVwWm1sal lXNTAgSUdO dmJuUnlhVy BKMWRHbHZi bk1nIGRHOG daR2x6Wlcg RnpaU0JsY2 1GayBhV05o ZEdsdmJpIE JoYm1RZ1ky OXUgZEhKdm JDQndjbSA5 bmNtRnRjeT RnIFNXNGdN VGs1T0Mgd2 dVR1pwZW1W eSBJR1J2Ym 1GMFpXIFFn TWpBd0lHMX AgYkd4cGIy NGdaRyA5el pYTWdiMlln IGRHaGxJR0 Z1ZEcgbGlh VzkwYVdNZy BXbWwwYUhK dmJXIEY0SU hSdklHWnAg WjJoMElIUn lZVyBOb2Iy MWhMQ0JoIE lHSnNhVzVr YVcgNW5JR1 Y1WlNCcCBi bVpsWTNScG IyIDR1UEdK eVBqWXUgSU ZCbWFYcGxj aSBCcGN5Qn JibTkzIGJp Qm1iM0lnYV ggUnpJSE4w Y205dSBaeU J5WlhObFlY IEpqYUNCaG JtUWcgWkdW MlpXeHZjRy AxbGJuUWdZ MkZ3IFlXSn BiR2wwYVcg VnpMQ0JwYm 5abCBjM1Jw Ym1jZ2IzIF psY2lBa09D QmkgYVd4c2 FXOXVJRyBW aFkyZ2dlV1 ZoIGNpQnBi aUJ5WlggTm xZWEpqYUNC aCBibVFnWk dWMlpXIHh2 Y0cxbGJuUX UgSUVsMElH aGhjeSBCdm RtVnlJRFl3 IE1DQnZibW R2YVcgNW5J SEpsYzJWaC BjbU5vSUhC eWIyIHBsWT NSeklHRmog Y205emN5Qj JZWCBKcGIz VnpJR1JwIG MyVmhjMlVn WVggSmxZWE 11UEdKeSBQ amN1SUZCbW FYIHBsY2lC b1lYTWcgWV NCc2IyNW5J RyBocGMzUn ZjbmtnIGIy WWdiV0Z1ZF cgWmhZM1Ix Y21sdSBaeU IyWVdOamFX IDVsY3l3Z2 FXNWogYkhW a2FXNW5JSC BSb1pTQjJZ V05qIGFXNW xJR1p2Y2kg QndibVYxYl c5aiBiMk5q WVd3Z1pHIG x6WldGelpT d2cgYldWdW FXNW5iMiBO dlkyTmhiQ0 JrIGFYTmxZ WE5sTEMgQm hibVFnWTJo cCBZMnRsYm 5CdmVDIDRn U1c0Z01qQX kgTUN3Z2RH aGxJRyBOdm JYQmhibmtn IFpHVjJaV3 h2Y0cgVmtJ Rzl1WlNCdi BaaUIwYUdV Z1ptIGx5Yz NRZ1EwOVcg U1VRdE1Ua2 dkbSBGalky bHVaWE1nIG FXNGdjR0Z5 ZEcgNWxjbk 5vYVhBZyBk MmwwYUNCQ2 FXIDlPVkdW amFDd2cgZD JocFkyZ2dh WCBNZ1ltVn BibWNnIGRY TmxaQ0IzYj MgSnNaSGRw WkdVdSBQR0 p5UGpndUlG IFJvWlNCam IyMXcgWVc1 NUlHaGhjeS BCaElHUnBk bVZ5IGMyVW djRzl5ZEcg WnZiR2x2SU c5bSBJSEJ5 YjJSMVkzIF J6TENCcGJt TnMgZFdScG JtY2djSCBK bGMyTnlhWE IwIGFXOXVJ RzFsWkcgbG phVzVsY3l3 ZyBkbUZqWT JsdVpYIE1z SUdGdVpDQm ogYjI1emRX MWxjaSBCb1 pXRnNkR2hq IFlYSmxJSE J5YjIgUjFZ M1J6TGlCVC BiMjFsSUc5 bUlHIGwwY3 lCM1pXeHMg TFd0dWIzZH VJRyBKeVlX NWtjeUJwIG JtTnNkV1Js SUUgeHBjR2 wwYjNJcyBJ RU5sYkdWaW NtIFY0TENC aGJtUWcgUV dSMmFXd3VQ RyBKeVBqa3 VJRkJtIGFY cGxjaUJvWV ggTWdZU0J6 ZEhKdiBibW NnWTI5dGJX IGwwYldWdW RDQjAgYnlC emRYTjBZVy BsdVlXSnBi R2wwIGVTQm hibVFnYUcg RnpJSE5sZE NCaCBiV0pw ZEdsdmRYIE 1nWjI5aGJI TWcgZEc4Z2 NtVmtkVyBO bElHbDBjeU JsIGJuWnBj bTl1YlcgVn VkR0ZzSUds dCBjR0ZqZE M0Z1NYIFFn YUdGeklIQn MgWldSblpX UWdkRyA4Z2 NtVmtkV05s IElHbDBjeU JuY20gVmxi bWh2ZFhObC BJR2RoY3lC bGJXIGx6Yz JsdmJuTXMg SUhkaGRHVn lJSCBWellX ZGxMQ0JoIG JtUWdkMkZ6 ZEcgVWdaMl Z1WlhKaCBk R2x2YmlCaW VTIEF5TUNV Z1lua2cgTW pBeU5TNDhZ biBJK01UQX VJRWx1IElE SXdNakFzSU YgQm1hWHBs Y2lCMyBZWE 1nYm1GdFpX IFFnYjI1bE lHOW0gSUhS b1pTQjNiMy BKc1pPS0Ft WE1nIGJXOX pkQ0JoWkcg MXBjbVZrSU dOdiBiWEJo Ym1sbGN5IE JpZVNCR2Iz SjAgZFc1bE lFMWhaMiBG NmFXNWxMQ0 J5IFlXNXJh VzVuSUcgWn Bjbk4wSUds dSBJSFJvWl NCd2FHIEZ5 YldGalpYVj AgYVdOaGJD QnBibSBSMW MzUnllUzRn IFNYUWdhR0 Z6SUcgRnNj MjhnWW1WbC BiaUJ5WldO dloyIDVwZW 1Wa0lHWnYg Y2lCcGRITW daRyBsMlpY SnphWFI1IE lHRnVaQ0Jw Ym0gTnNkWE 5wYjI0ZyBa V1ptYjNKMG N5IHdnWldG eWJtbHUgWn lCaElITndi MyBRZ2IyNG dkR2hsIElE SXdNakVnUk cgbDJaWEp6 YVhSNSBTVz VqSUZSdmND IEExTUNCRG IyMXcgWVc1 cFpYTWdabS A5eUlFUnBk bVZ5IGMybD BlU0JzYVgg TjBMZz09Ci AgICAgICAg PC9zcGFuPg ogICAgICAg IAogICAgIC AgIA==